Pharmacology and therapeutic potential of sigma(1) receptor ligands.
Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. · 2008
Read Pharmacology and therapeutic potential of sigma(1) receptor ligands. by Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2701284.txt.
Introduction
Cobos and colleagues reviewed in 2008 the sigma-1 receptor, an enigmatic protein once mistaken for an opioid receptor, and the drugs that bind it. The receptor is unlike any other known protein in sequence. It lives largely in the cell's internal membranes, where it tunes calcium signals, and it also adjusts ion channels and several neurotransmitter systems, most notably glutamate.
Its binding list is a who's who of brain drugs: the antipsychotic haloperidol, antidepressants such as fluvoxamine, and stimulants such as cocaine and methamphetamine all grip it. Certain steroids made in the body may be its natural partners. Animal studies tie its activity to memory, mood, pain, and drug craving. That breadth makes its ligands candidates across psychiatry and pain medicine, and blockers of it candidates against stimulant abuse. The review gathers the behavioral evidence behind each claim.
Catalog record
| CREATOR | Cobos EJ, Entrena JM, Nieto FR, Cendán CM, Del Pozo E. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 116 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands By E.J Cobos, J.M Entrena, F.R Nieto, C.M Cendán, E Del Pozo Published in: Current Neuropharmacology DOI: 10.2174/157015908787386113 ABSTRACT Sigma (σ) receptors, initially described as a subtype of opioid receptors, are now considered unique receptors. Pharmacological studies have distinguished two types of σ receptors, termed σ1 and σ2. Of these two subtypes, the σ1 receptor has been cloned in humans and rodents, and its amino acid sequence shows no homology with other mammalian proteins. Several psychoactive drugs show high to moderate affinity for σ1 receptors, including the antipsychotic haloperidol, the antidepressant drugs fluvoxamine and sertraline, and the psychostimulants cocaine and methamphetamine; in addition, the anticonvulsant drug phenytoin allosterically modulates σ1 receptors. Certain neurosteroids are known to interact with σ1 receptors, and have been proposed to be their endogenous ligands. These receptors are located in the plasma membrane and in subcellular membranes, particularly in the endoplasmic reticulum, where they play a modulatory role in intracellular Ca2+ signaling. Sigma1 receptors also play a modulatory role in the activity of some ion channels and in several neurotransmitter systems, mainly in glutamatergic neurotransmission. In accordance with their widespread modulatory role, σ1 receptor ligands have been proposed to be useful in several therapeutic fields such as amnesic and cognitive deficits, depression and anxiety, schizophrenia, analgesia, and against some effects of drugs of abuse (such as cocaine and methamphetamine). In this review we provide an overview of the present knowledge of σ1 receptors, focussing on σ1 ligand neuropharmacology and the role of σ1 receptors in behavioral animal studies, which have contributed greatly to the potential therapeutic applications of σ1 ligands. HISTORICAL OVERVIEW: DISCOVERY OF SIGMA RECEPTORS AND SIGMA RECEPTOR SUBTYPES Sigma (σ) receptors were first described as a subclass of opioid receptors [102] to account for the psychotomimetic actions of (±)-SKF-10,047 (N-allylnormetazocine) and other racemic benzomorphans. This early confusion was due to the complex pharmacology of this racemic compound; later studies showed that (–)-SKF-10,047 binds to µ and κ opioids, whereas the (+)-isomer lacks affinity for opioid receptors but binds to PCP (phencyclidine) binding sites with low affinity, and to a different site with high affinity, which currently retains the designation of σ [reviewed in 112 and 124] amongst others. Two different σ sites were distinguished based on their different drug selectivity pattern and molecular mass; these two σ sites are now known as σ1 and σ2 receptors [64]. It was reported that σ1 binding sites display stereospecificity towards dextrorotatory isomers of benzomorphans, whereas σ2 binding sites display reverse selectivity, i.e., levorotatory isomers display higher affinity than dextrorotatory isomers of σ ligands [e.g. 64, 165]. The molecular weight was found to differ between the two σ receptors subtypes: the σ1 receptor is a 29-kDa single polypeptide first cloned in 1996 [55], whereas σ2 receptors have not yet been cloned and have an apparent molecular weight of 18-21.5 kDa according to photolabeling studies [65, 159]. In spite of intensive efforts in research on the σ2 subtype in recent years [partially reviewed in 14; 142, 156, 114], the σ1 subtype is much better characterized, and is the focus of this review. Sigma1 receptors have been thoroughly studied in an attempt to elucidate their possible neuropharmacological applications, mainly in learning and memory processes, depression and anxiety, schizophrenia, analgesia and some effects of certain drugs of abuse. In this review we describe some aspects of the general biology of σ1 receptors, but focus on σ1 ligand neuropharmacology and the role of σ1 receptors in behavioral animal studies, which have contributed greatly to the understanding of the possible neuropharmacological properties of σ1 receptors. Non-neuropharmacological effects of σ1 ligands such as cardiovascular effects or their effects on cancer and immunity, and their antitussive effects, are not covered in this review. Therefore this review will not go into detail on some aspects of σ1 receptor knowledge, and not all references will be cited. MOLECULAR CHARACTERISTICS, DISTRIBUTION AND PHARMACOLOGICAL PROFILE OF SIGMA1 RECEPTORS Cloning and Structure of σ1 Receptors Significant progress in our knowledge of σ receptors was made when the σ1 receptor was cloned. The σ1 receptor is a 29-kDa single polypeptide which was first cloned in guinea-pig liver [55], and later in mouse kidney, a JAR human choriocarcinoma cell line, and in the rat and mouse brain [reviewed in 54]. The protein is composed by 223 amino acids and shows the typical σ1 binding profile [55, 84, 180]. The amino acid sequence of the σ1 receptor cloned from the human cell line is highly homologous to the σ1 receptor cloned from the other species [181], and shows no homology with other mammalian proteins, but shares approximately 30% identity with the yeast gene that encodes the C7–C8 sterol isomerase [141], and contains an endoplasmic reticulum retention signal at the NH2 terminus [55, 179]. Cloning of the σ1 receptor has contributed greatly to research in this field, making it possible to design specific antisense oligodeoxynucleotides to study σ1 receptor function (as will be described below) and develop σ1-receptor knockout mice [91]. Several structures have been proposed for σ1 receptors. Initial studies proposed a single transmembrane domain structure [43, 55]. More recently, Aydar and coworkers presented evidence that the σ1 receptor in the plasma membrane has two transmembrane segments (when expressed in Xenopus laevis oocytes) with the NH2 and COOH termini on the cytoplasmic side of the membrane [3]. Recent studies proposed that in addition to the hydrophobic regions that constitute the putative transmembrane domains, there are two additional hydrophobic segments (one of them partially overlapping the second transmembrane domain), which were proposed to be steroid binding domain-like sites [27], and suggesting the existence of two different domains for ligand binding in the σ1 receptor [159], as previously proposed in earlier experiments [12]. This proposed model is illustrated in Fig. (1). The pharmacological characterization of these putative domains merits further study. Anatomical and Subcellular Distribution of σ1 Receptors Anatomical Distribution of σ1 Receptors 2.2.1 At the anatomical level σ1 receptors are widely distributed in peripheral organs [e.g. 192] and different areas of the central nervous system, where they have been thoroughly studied. They are widely distributed in the brain, but concentrated in specific areas involved in memory, emotion and sensory and motor functions [reviewed in 9, 54 and 146]. In these studies high to moderate levels of σ1 receptors were associated with the hippocampus, especially in the dentate gyrus, hypothalamus, olfactory bulb, several cortical layers, pons, the septum, the central gray, locus ceruleus, dorsal raphe, the substantia nigra pars compacta, the red nucleus and various motor cranial nerve nuclei. The cerebellum is not particularly enriched in σ1 receptors, although some of its areas, such as the Purkinje cell layer, have been reported to show considerable densities of σ1 receptors. In addition to the brain, σ1 receptors are also numerous in the spinal cord, mainly in the superficial layers of the dorsal horn [2]. Subcellular Distribution of σ1 Receptors 2.2.2 The subcellular distribution of σ1 receptors was firstly studied with radioligand binding in subcellular fractions, and more recently with immunochemical methods. Binding experiments with the σ1 radioligands [3H](+)-SKF-10,047, [3H](+)-3-PPP and [3H](+)-pentazocine showed that σ1 receptors are located in several types of mouse, rat and guinea pig brain membrane.